No Benefit For Adjuvant Ibandronate At 3 Years In Early Breast Cancer

No benefit for adjuvant ibandronate at 3 years in early breast cancer

Minckwitz: Adjuvant Ibandronate in Elderly Breast Cancer Patients

Cancer Therapy Advisor

Optimizing Adjuvant Treatment of Early Breast Cancer: Where Are We Today?

3 Year Cancer Survivor - Stage 4 Breast Cancer at 22 #shorts

Dr. Burstein on Adjuvant Endocrine Therapy for ER+ Breast Cancer

TALENT: neoadjuvant T-DXd with or without anastrozole for HER2-low, HR+ early stage breast cancer

The benefits of adjuvant CDK4/6 and PARP inhibition in breast cancer

Adjuvant trastuzumab did not improve outcomes for patients with HER2-low breast cancer

Are bisphosphonates an effective treatment for early stage breast cancer?

Final results of the phase 3 DATA trial assessing aromatase inhibition in HR+ breast cancer

Dr. Brufsky on Adjuvant Bisphosphonates for Patients with Breast Cancer

Denosumab improves disease-free survival for postmenopausal HR-positive breast cancer

Dr. Brufsky Discusses Adjuvant Bisphosphonates as a New Standard of Care

Targeted Oncology

Discussion in clinic about adjuvant bone therapy in breast cancer

Differential long-term benefit of adjuvant tamoxifen in ER+/HER2- premenopausal + postmenopausal BC

Adjuvant chemotherapy in elderly ER HER2- breast cancer patients

Optimal neoadjuvant and adjuvant therapy for patients with early TNBC

Adjuvant capecitabine did not significantly improve outcomes for breast cancer patients

SABCS2014: The phase III ICE study (Ibandronate) - Gunter von Minckwitz

Bone Drug Fails to Stop Breast Cancer